SCHEMBL2827117

SCHEMBL2827117

O=C(Cn1cnc2ccccc21)Nc1nc(-c2ccc(Cl)cc2Cl)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.53
▸ LMNA P02545 4/20 0.53
▸ MAPT P10636 4/20 0.52
▸ RORC P51449 3/20 0.52
▸ HPGD P15428 2/20 0.47
▸ MGLL Q99685 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ CCKAR P32238 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ GPR55 Q9Y2T6 1/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829180 0.86 MAPT (0.60) SMN1; SMN2MAPTMGLLKDM4ENPC1
SCHEMBL2826735 0.86 SMN1; SMN2 (0.49) SMN1; SMN2LMNAMAPTRORCHPGD
SCHEMBL2830760 0.86 ABL1 (0.56) SMN1; SMN2MAPTRORCMGLLHTT
SCHEMBL2826708 0.84 ABL1 (0.57) SMN1; SMN2LMNAMAPTMGLLHTT
SCHEMBL2827621 0.83 ABL1 (0.57) SMN1; SMN2MAPTMGLLNPC1KMT2A
SCHEMBL2830098 0.83 SMN1; SMN2 (0.54) SMN1; SMN2LMNAMAPTHPGDMGLL
SCHEMBL2825544 0.82 MAPT (0.64) SMN1; SMN2LMNAMAPTMGLLMAPK1
SCHEMBL2826747 0.82 SMN1; SMN2 (0.48) SMN1; SMN2LMNAMAPTHPGDMAPK1
SCHEMBL2827337 0.81 ABL1 (0.58) SMN1; SMN2LMNAMAPTHPGDMGLL
SCHEMBL1037761 0.80 KDM4E (0.62) SMN1; SMN2LMNAMAPTHPGDMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948650-B1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS ORGANON NV (NL) 2010-05-26 — — EP claimed
US-20100099722-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES MSD OSS B.V. (NL) 2010-04-22 — — US claimed
EP-1948650-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS N.V. Organon (NL) 2008-07-30 — — EP claimed
WO-2007054474-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS N.V. ORGANON (NL) 2007-05-18 — — WO claimed
US-20070105920-A1 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives AKZO NOBEL N.V. (NL) 2007-05-10 — — US claimed
EP-1948650-B1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS ORGANON NV (NL) 2010-05-26 — — EP disclosed
US-20100099722-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES MSD OSS B.V. (NL) 2010-04-22 — — US disclosed
EP-1948650-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS N.V. Organon (NL) 2008-07-30 — — EP disclosed
WO-2007054474-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS N.V. ORGANON (NL) 2007-05-18 — — WO disclosed
US-20070105920-A1 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives AKZO NOBEL N.V. (NL) 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105920-A1 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives TRPV1, TRPV3, TRPV4 SMN1; SMN2 2525/4885LMNA 3121/4885MAPT 2205/4885
US-20100099722-A1 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES TRPV1, TRPV3, TRPA1 SMN1; SMN2 2468/4885LMNA 3347/4885MAPT 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback